ESR1 will be hosted by Dr. Bernardes at IMM.
Project Title: Metal-Mediated Site-selective Modification of Proteins at Tryptophan.
Objectives: Development of two metal-based complementary methods for the chemical-site selective protein modification of proteins at tryptophan (Trp).
Expected Results: To establish Trp as a target to achieve chemically-defined protein conjugates.

ESR2 will be hosted by Dr. Bernardes at IMM and Dr. Pedro Gois at FFUL.
Project Title: Chemical site-selective functionalization of proteins with boronic acids.
Objectives: To create more stable homogeneous conjugates based on cysteine functionalization.
Expected Results: Implementation of a direct addition of thiols to synthetically versatile boronated styrenes.

ESR3 will be hosted by Dr. Pedro Gois at FFUL.
Project Title: Synthesis of therapeutically useful conjugates based on site-selective lysine modification.
Objectives: Development of a site-selective protein modification based on lysine residues.
Expected Results: A new method for the preparation of chemically-defined protein conjugates based on available lysines.

ESR4 will be hosted by Prof. Stephen Caddick at UCL.
Project Title: Providing an ideal platform for next-generation antibody-drug conjugates (ADCs).
Objectives: Generation of disulfide bridged, dual modified antibody fragments and full antibodies.
Expected Results: A new method for dual functionalising of antibodies.

ESR5 will be hosted by Prof. Tanja Weil at UULM
Project Title: Supramolecular Protein-Drug Conjugates as Precision Therapeutics
Objectives: This project aims to establish salicylhydroxamate as a “clikable” handle to modify proteins and assemble ADCs
Expected Results: We expect in this project to generate precise supramolecular conjugates between model peptide somatostatin and a CXCR4 antibody with bortezomib via conjugation with a bis-alkylation reagent containing salicylhydroxamate

ESR6 will be hosted by Dr. Francisco Corzana at Uni. La Rioja.
Project Title: Design of novel biosensors for tumours based on site-selective modification of anti-MUC1-antibodies.
Objectives: Design of unique anti-MUC1-antibodies with high affinity and selectivity for modified MUC1 glycopeptides. Site-selective modification of anti-MUC1 antibodies to conjugate with different fluorophores and radiolabels.
Expected Results: To use anti-MUC1 antibodies conjugates as a potential biosensor for detecting tumours in vivo.

ESR7 will be hosted by Dr Tuomas Knowles at Uni. Cambridge.
Project Title: Microfluidic route to multivalent protein nanoparticles for selective targeting in vivo.
Objectives: Develop a microfluidic setup for the generation of monodisperese protein nanoparticles that are susceptible to surface modification to study of the role of multivalency for effective targeting using small molecule ligands specific to disease-associated protein targets.
Expected Results: By the end of this project, we will have explored a new class of nanomaterial constructed from proteins and used it as a probe of the factors that determine and limit small molecule targeting of specific cells in vivo. By control of the size and ligand functionalisation density we will explore a range of interaction energies with cell receptors and will correlate in vitro measurements of binding with targeting efficacy in vivo.

ESR8 will be hosted by Dr Ludger Johannes at Institut Curie.
Project Title: Synthetic lectins for targeted cancer therapy.
Objectives: To generate synthetic lectins that bind glycosphingolipids for clathrin-independent uptake into cells; analyze endocytic membrane remodelling driven by synthetic lectins and finally to apply synthetic lectin design to target cancer cells.
Expected Results: A new synthetic platform based on lectins for the targeted delivery of drugs into cancer cells.

ESR9 will be hosted by Prof Christian Becker at Uni. Vienne.
Project Title: Posttranslationally modified Silaffins as Tools for Drug Delivery.
Objectives: To establish site-selective chemistry to link cargo (small molecules up to proteins) modified to Silaffins as tools for drug delivery via biomimetic particles.
Expected Results: A new platform for functionalizing Silaffins and show their utility for selective drug release.

ESR10will be hosted by Dr. Bernades at IMM Project
Project Title: Investigating the selective cytotoxicity of cancer cells
Objectives: Development of a small molecule drug conjugate which can be used to  target cancer cells. Development of a pair of peptide fragments which can ligate bioorthogonally at the site of the tumour.
Expected Results: Two novel strategies for targeting cancer cells.


Copyright © 2015 Protein Conjugates All Rights Reserve